search
Back to results

Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness

Primary Purpose

Chronic Dizziness

Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
SpotOn's corrective elements for dizziness
Placebo
Sponsored by
Meir Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Dizziness focused on measuring Phobic Postural Vertigo, Visual Vertigo, Chronic Subjective Dizziness, Motion and Space Discomfort, SpotOn

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age: 18≤ years ≤85
  • Clinical diagnosis of chronic dizziness primary or secondary to vestibular disorder.
  • Stable symptoms for more than one month and less than a year.
  • Ability to perform all tests (including computerized test) and interviews.
  • Gave informed consent for participation in the study.

Exclusion Criteria:

  • Dizziness disease with fluctuating symptoms such as in active Meniere's disease or Benign Paroxysmal Positional Vertigo
  • CNS disease or injuries
  • Dizziness caused as a result of previous whiplash
  • Any active or non-controlled disease that might cause dizziness (e.g. non-controlled diabetes, hypertension, anemia, respiratory, cardiovascular or endocrinological disorder etc.)
  • Pregnant women
  • Participation currently in another clinical study or enrolled in another clinical study within 30 days prior to this study.

Sites / Locations

  • Dept Neurology, Meir Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

SpotOn's corrective elements

Placebo corrective elements

Arm Description

Outcomes

Primary Outcome Measures

Dizziness Handicap Inventory (DHI)
The change from baseline in dizziness symptoms as measured by Dizziness Handicap Inventory (DHI) The change from baseline in balance as measured by the Activities-specific and Balance Confidence (ABC) Scale. Safety:AE incidence Physical, neuro-otologic and neurological examination Static/dynamic/positioning examination

Secondary Outcome Measures

Vertigo Symptom Scale-Short Form
Vertigo Symptom Scale-Short Form
Visual Vertigo Analog Scale (VVAS)
Visual Vertigo Analog Scale (VVAS)
The Activities-specific Balance Confidence (ABC) Scale
The Activities-specific Balance Confidence (ABC) Scale
Clinical Global Impressions-Improvement (CGI-I) scale
Clinical Global Impressions-Improvement (CGI-I) scale
Berg Balance Scale (BBS)
Berg Balance Scale (BBS)
Beck Anxiety Inventory (BAI)
Beck Anxiety Inventory (BAI)

Full Information

First Posted
October 25, 2011
Last Updated
May 9, 2018
Sponsor
Meir Medical Center
Collaborators
SpotOn Therapeutics Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01460121
Brief Title
Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness
Official Title
A Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
October 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Meir Medical Center
Collaborators
SpotOn Therapeutics Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The diagnosis and management of acute vertigo and dizziness is most of the time an easy task for the general practitioner. However, following an acute vestibular disorder and very often with no any overt cause, a considerable number of patients complain on chronic dizziness and subjective disturbance of balance despite normal clinical and laboratory tests. Patients describe that perceptual visual stimulus provoke or aggravate their symptoms that are frequently accompanied by anxiety. These cases have been described in the medical literature as Phobic Postural Vertigo, Visual Vertigo, Chronic Subjective Dizziness and Motion and Space Discomfort (2,3,4,5). Treatment of these conditions includes physical therapy (similar to vestibular rehabilitation exercises) and anti-anxiety or anti-depressant agents such as benzodiazepines and SSRI, however, the effectiveness of these approaches is debatable. Because visual stimuli play a crucial role in space orientation and motion perception, it is reasonable to hypothesize that certain visual stabilizing signals applied on the peripheral visual field (that is involved mainly in the perception of motion) could be of help in patients suffering from dizziness. This is the rationale of a new technology (SMB- Senso Mental Balance Technology) developed to alleviate the feelings of dizziness. Trial is conducted in Meir Medical Center, Israel. Recruitment only in Israel!

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Dizziness
Keywords
Phobic Postural Vertigo, Visual Vertigo, Chronic Subjective Dizziness, Motion and Space Discomfort, SpotOn

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SpotOn's corrective elements
Arm Type
Experimental
Arm Title
Placebo corrective elements
Arm Type
Placebo Comparator
Intervention Type
Device
Intervention Name(s)
SpotOn's corrective elements for dizziness
Intervention Description
Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
Intervention Type
Device
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Dizziness Handicap Inventory (DHI)
Description
The change from baseline in dizziness symptoms as measured by Dizziness Handicap Inventory (DHI) The change from baseline in balance as measured by the Activities-specific and Balance Confidence (ABC) Scale. Safety:AE incidence Physical, neuro-otologic and neurological examination Static/dynamic/positioning examination
Time Frame
After 4 weeks of treatment
Secondary Outcome Measure Information:
Title
Vertigo Symptom Scale-Short Form
Description
Vertigo Symptom Scale-Short Form
Time Frame
After 4 weeks of treatment
Title
Visual Vertigo Analog Scale (VVAS)
Description
Visual Vertigo Analog Scale (VVAS)
Time Frame
After 4 weeks of treatment
Title
The Activities-specific Balance Confidence (ABC) Scale
Description
The Activities-specific Balance Confidence (ABC) Scale
Time Frame
After 4 weeks of treatment
Title
Clinical Global Impressions-Improvement (CGI-I) scale
Description
Clinical Global Impressions-Improvement (CGI-I) scale
Time Frame
After 4 weeks of treatment
Title
Berg Balance Scale (BBS)
Description
Berg Balance Scale (BBS)
Time Frame
After 4 weeks of treatment
Title
Beck Anxiety Inventory (BAI)
Description
Beck Anxiety Inventory (BAI)
Time Frame
After 4 weeks of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: 18≤ years ≤85 Clinical diagnosis of chronic dizziness primary or secondary to vestibular disorder. Stable symptoms for more than one month and less than a year. Ability to perform all tests (including computerized test) and interviews. Gave informed consent for participation in the study. Exclusion Criteria: Dizziness disease with fluctuating symptoms such as in active Meniere's disease or Benign Paroxysmal Positional Vertigo CNS disease or injuries Dizziness caused as a result of previous whiplash Any active or non-controlled disease that might cause dizziness (e.g. non-controlled diabetes, hypertension, anemia, respiratory, cardiovascular or endocrinological disorder etc.) Pregnant women Participation currently in another clinical study or enrolled in another clinical study within 30 days prior to this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos Gordon, Prof
Organizational Affiliation
Meir Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dept Neurology, Meir Medical Center
City
Kfar Saba
ZIP/Postal Code
44281
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness

We'll reach out to this number within 24 hrs